213 related articles for article (PubMed ID: 9420050)
1. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
Di Modugno E; Broggio R; Erbetti I; Lowther J
Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
Edwards JR
New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
9. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
[TBL] [Abstract][Full Text] [Related]
12. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
Tsuji M; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
Antimicrob Agents Chemother; 1998 Jan; 42(1):94-9. PubMed ID: 9449267
[TBL] [Abstract][Full Text] [Related]
15. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
16. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
[TBL] [Abstract][Full Text] [Related]
17. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.
Yamaguchi K; Domon H; Miyazaki S; Tateda K; Ohno A; Ishii K; Matsumoto T; Furuya N
Antimicrob Agents Chemother; 1998 Mar; 42(3):555-63. PubMed ID: 9517932
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
[TBL] [Abstract][Full Text] [Related]
20. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]